Multiple Myeloma Coverage from Every Angle

ASH 2021: Novel BCMA-Targeting Bispecific Antibody Under Study in Resistant Myeloma

By: Joseph Fanelli
Posted: Thursday, December 23, 2021

According to findings presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 900), TNB-383B, a B-cell maturation antigen (BCMA)-targeting bispecific antibody, is well tolerated among patients with relapsed and refractory multiple myeloma, with an objective response rate of 79% in the dose-escalation cohort of a phase I trial. Shaji K. Kumar, MD, of the Mayo Clinic, Rochester, Minnesota, and colleagues noted that enrollment into the dose-expansion arm is ongoing.

In this early-phase study, the authors reported on 118 evaluable patients with relapsed or refractory multiple myeloma who received TNB-383B. Approximately 75 patients received at least 40 mg in the dose-escalation plus dose-expansion phase.

The authors reported that treatment-related adverse events occurred in 54 patients (46%), with 37 of these patients having received at least 40 mg. Adverse events related to infection occurred in 38 patients (32%), with 23 patients having received at least 40 mg. The most common treatment-related adverse events were cytokine-release syndrome (52 patients), neutropenia (24 patients), and anemia (21 patients).

After a median follow-up of 8 months, for patients who received at least 40 mg of TNB-383B every 3 weeks, the objective response rate was 81%, with a very good partial response or better rate of 69%. At the same dosage in the combined dose-escalation and -expansion cohorts (60 patients), the authors observed an objective response rate of 60%, with a median follow-up of 4.3 months. These patients reported a very good partial response rate of 40%.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.